Home
Goodwin Procter LLP
Beth Ashbridge, Ph.D.
Beth Ashbridge, Ph.D.
Goodwin Procter LLP
FDA Approves BMS And J&J CAR-T Cell Therapies For The Earlier Treatment Of Multiple Myeloma
17 Apr 2024 | United States
Women's History Month Spotlight: Emmanuelle Charpentier And Jennifer Doudna
26 Mar 2024 | United States
Goodwin Releases Update To Its Comprehensive Guide To Biosimilars Litigation And Regulation In The U.S.
16 Jan 2024 | United States
German Court Invalidates CureVac Patent In Ongoing BioNTech Lawsuit
08 Jan 2024 | United States
Year In Review: Top Deals In 2023
05 Jan 2024 | United States
Acuitas Files Suit Against CureVac Alleging Incorrect Inventorship On COVID MRNA-LNP Vaccine Patent Family
24 Nov 2023 | United States
Amneal Expands Oncology Offering With Two Denosumab Biosimilars
24 Oct 2023 | United States
Celltrion Expands Access To YUFLYMA (Adalimumab-Aaty)
19 Oct 2023 | United States
Acuitas Seeks Declaratory Judgment Of Non-Infringement And Invalidity Against Arbutus And Genevant In New Jersey Court Challenging MRNA-Delivery Specific Patents
14 Aug 2023 | United States
Biocon Completes Integration Of Viatris Biosimilars Business
11 Jul 2023 | Worldwide
Regeneron Received FDA Complete Response Letter For Its Higher Dose Aflibercept Injection BLA
10 Jul 2023 | United States
Alnylam Files New COVID-19 Vaccine Infringement Lawsuits Against Pfizer And Moderna
06 Jun 2023 | United States
Insulin Updates: March 2023
28 Mar 2023 | United States
PTAB Institutes Mylan's Two EYLEA (Aflibercept) IPRs
20 Jan 2023 | United States
Celltrion Obtains Canadian Approval To Sell Bevacizumab Biosimilar
20 Jan 2023 | United States
Celltrion And Rani Therapeutics To Jointly Develop Oral Formulation Of Ustekinumab Biosimilar
12 Jan 2023 | United States
Contact Details
London
Email Website
London
UK

  © Mondaq® Ltd 1994 - 2024. All Rights Reserved.